Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume & ASP by Technology Type, Product & Application The global live cell imaging market size was $1.95 billion in 2021 and is predicted to reach $4.18 billion by 2030, representing a CAGR of 8.8% throughout the period of 2021-2030. As of 2020, North America has the greatest market share. A larger patient pool and an expanding geriatric population are responsible for the increase. The region's major drivers are the substantial investment and financing available for live-cell imaging research. As the name implies, live-cell imaging is a technique that involves imaging cells while they are still living, usually in their growing media. It is a sophisticated imaging technique that gives real-time spatiotemporal changes in subcellular events, thus allowing researchers for a better understanding of cellular structures and functions. In recent years, live cell imaging has become a requisite analytical tool for addressing pertinent questions in several areas of biological and biomedical sciences, including cancer research, neuroscience, cell biology, developmental biology, and pharmacology. According to the American Cancer Society, 1,806,590 new cancer cases will be detected in 2020, including 1,91,930 instances of prostate cancer, 2,79,100 cases of breast cancer, and 2,28,820 lung cancer cases. Technology has changed how scientists and researchers study cellular processes, proteins, molecular interactions and internal structures of cells and understand various biological functions. As a result, more precise information can be obtained using live cell imaging, which is vital for immunology, microbiology, genetics and neurology. Market Dynamics: - Market Drivers: - (A rise in the adoption of high content screening in drug discovery, Impact of Covid and rising issue of chronic diseases) HCS (High Content Screening) ensures that the whole process is cost and time-efficient. High content screening for toxicity studies is predicted to increase during the forecasted period, which is expected to drive the market as live-cell imaging is a vital part of High content screening to get meaningful observations. According to research published in Archives of Toxicology in October 2019 titled "Review of High-content Screening (HCS) Applications in Toxicology. “High content screening is used in various in-vitro toxicity research studies such as developmental toxicity, genotoxicity, developmental neurotoxicity, hepatotoxicity, cardiotoxicity, and nephrotoxicity". According to WHO, in 2019, around 17 million people died because of cardiovascular diseases (32% of global deaths). This means that the high mortality and prevalence rate associated with CVDs increase the demand for live-cell imaging equipment. According to the World Health Organization (WHO), chronic illness will rise by 57% by 2020. The market for live cell imaging is growing due to the rising prevalence of chronic illness, which necessitates greater and faster diagnostic capabilities. According to the WHO, there were over 33 million confirmed cases of COVID-19 as of September 29, 2020, with 1 million deaths, with the Americas having the largest number of deaths, followed by Europe and Southeast Asia. Furthermore, the rising demand for various live-cell imaging technologies and processes like live-cell marker, live-cell imaging buffer, live-cell imaging incubator, nanolive imaging, live-cell imaging organoids, live-cell imaging reagents, t cell imaging, live-cell imaging endocytosis, 3d live-cell imaging, live-cell imaging apoptosis, f-actin live-cell imaging, fluorogenic probes for live-cell imaging of the cytoskeleton, live-cell imaging antibodies, live-cell imaging histopathology, live-cell imaging biosensor are also driving the overall market growth worldwide. Restraints: - (High cost of HCS systems) High content screening systems come with advanced features; therefore, they are priced at a premium rate. For example, the cost of a confocal microscope is more than $250,000, and the cost of a wide-field microscope is more than $100,000. So, due to the higher costs of these systems, it is becoming daunting for the common netizens to afford them, thereby hindering the overall market growth. Additionally, to the high procurement cost of these systems, the maintenance costs and several indirect expenses also increase the overall cost of these instruments. Opportunities: - (Untapped opportunities of the emerging markets) Countries such as Brazil, China, India, and Russia are emerging players in the live cell imaging market and have significant opportunities for live-cell imaging systems because of growing R&D activities for various organizations in these countries. According to a study issued by the National Bureau of Statistics, China's overall R&D expenditure was roughly 2.79 trillion yuan (about $441.13 billion) in 2021, rising 14.2 % year on year. China has Contract research organizations (CROs) that provide clinical research services to pharma companies. The increasing growth of clinical research in China is expected to augment the future growth opportunities for live-cell imaging. According to the Pharma intelligence centre, the percentage of clinical trials has increased exponentially over the years, from 1% in 2000 to around 21% in 2019. Global Live cell imaging Market Analysis of Different Segmentations: The industry segmentation is based on Product, Application, Technology, and Region. Based on Product Equipment Software Consumables Based on Application Cell Biology Stem Cell & Drug Discovery Developmental Biology Based on Technology High content screening (HCS) Fluorescence recovery after photobleaching (FRAP) Time-lapse microscopy Fluorescence resonance energy transfer (FRET) Based on Regions North America The U.S. Canada Mexico Rest of North America Europe Germany U.K Russia Switzerland Rest of Europe Asia Pacific China India Japan Australia Rest of APAC LAMEA UAE Saudi Arabia Others Based on the product segment, Equipment dominated the market with a share of around 39%. The standalone system from the equipment segment is expected to hold a significant percentage. These systems can function without any other hardware. According to the Prior Scientific Instruments Ltd. update from October 2021, live events occurring in these samples must also be tracked in three-dimensional space to allow for the most effective gathering of 3D picture data. Major factors that are driving this segment are the multiple uses of these systems in live-cell imaging and the increased focus on R&D. Based on Application, The Cell Biology segment held the largest live cell imaging market share due to the rising number of research works on molecular interaction networks. Apart from this, the advanced illumination systems and filter techniques are some innovative technologies that drive the process extensively. On the basis of Technology, the Fluorescence resonance energy transfer segment held the largest share because of its various advantages in ascertaining the spatial proximity in the protein levels. Furthermore, this technology became popular in recent times due to the increase in the Application of genetic peptides. The research 'Studying SARS-CoV-2 with Fluorescence Microscopy,' released in 2021, found that a fluorescent microscope may be utilized to successfully examine the molecular biology of SARS-CoV-2 and similar viruses. The market is expected to develop as more live cell imaging equipment is used to research the molecular biology of the COVID-19 virus. Based on Region, North America has the largest industry share as of 2020. A bigger patient pool and an expanding senior population are responsible for the majority of the increase. The region's major drivers are the substantial investment and financing available for live-cell imaging research. Due to variables such as an increasing number of chronic illnesses and a growing number of R&D programmes in the nation, the United States has the greatest market share in the North American area. According to the Centres for Disease Control and Prevention, around 34,800 new HIV infections occurred in the United States in 2020. According to the same source, over 13% of HIV-positive people in the United States are unaware of their status and require a prompt diagnosis. Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 1.95 billion Revenue forecast in 2030 USD 4.18 billion Growth rate CAGR of approximately 8.8% Base year for estimation 2021 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Application, By Technology, By Region By Product Equipment, Software, Consumables By Application Cell Biology, Stem Cell & Drug Discovery, Developmental Biology By Technology High content screening (HCS), Fluorescence recovery after photobleaching (FRAP), Time-lapse microscopy, Fluorescence resonance energy transfer (FRET) By Region Asia Pacific, North America, Europe, LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Danaher Corporation, Carl Zeiss AG, Nikon Corporation, Olympus Corporation, PerkinElmer, Inc., G.E. Healthcare, Bruker Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc., CytoSMART Technologies, NanoEnTek Inc., Phase Focus Limited, Tomocube Inc., Phase Holographic Imaging PHI AB, B.D. Biosciences, Sony Biotechnology Inc., Merck KGaA, KEYENCE Corporation, ibidi GmbH, Bio-Rad Laboratories, Logos Biosystems, and Nanolive SA. Cost & acquiring options Get hold of customized purchase options to fulfil your niche research needs. Global Live cell imaging Market Competitive Landscape Analysis The competitive landscape analysis provides information about the crucial competitors prevailing in the worldwide market environment. The comparison is performed based on overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, etc. The key players that are included in the report are: Danaher Corporation (U.S.) Carl Zeiss AG (Germany) Nikon Corporation (Japan) Olympus Corporation (Japan) PerkinElmer, Inc. (U.S.) G.E. Healthcare (U.S.) Bruker Corporation (U.S.) Thermo Fisher Scientific Inc. (U.S.) Sartorius AG (Germany) Oxford Instruments (U.K.) BioTek Instruments (US) Etaluma, Inc. (U.S.) Deepcell Inc. CytoSMART Technologies (Netherlands) NanoEnTek Inc. (Korea) Phase Focus Limited (U.K.) Tomocube, Inc. (South Korea) Phase Holographic Imaging PHI AB (Sweden) B.D. Biosciences (U.S.) Sony Biotechnology, Inc. (U.S.) Merck KGaA (Germany) KEYENCE Corporation (Japan) ibidi GmbH (Germany) Bio-Rad Laboratories (U.S.) Logos Biosystems (South Korea) Nanolive SA (Switzerland). Recent Developments In February 2022, TGen and Deepcell cooperated to categorize and isolate sick cells using artificial intelligence-based technologies. Deepcell's AI-powered Technology turns cell morphology into a quantitative, high-throughput marker that may be used in research to supplement existing molecular procedures or as a standalone tool. In August 2021, CytoSMART announced that they would launch CytoSMART Lux3 BR. It is a new type of brightfield microscope, i.e., a live-cell imaging microscope equipped with a high-quality CMOS camera to assist label-free cell imaging procedures. In March 2021, Researchers from Heidelberg University and the Karlsruhe Institute of Technology (KIT) discovered a novel fluorescent imaging approach that enables live-cell RNA imaging with an unprecedented resolution to better understand the exact activities. The approach is based on the Rhodamine-Binding Aptamer for Super-Resolution Imaging Techniques, a unique molecular marker (RhoBAST). In January 2021, the Zeiss group announced that they would launch Zeiss Visioner 1, a Zeiss live cell imaging system, an innovative digital microscope that facilitates real-time all-in-one focus via a micro-mirror array system. In July 2020, Etaluma, Inc. and InnoME, Gmbh established a cooperation to deliver entry-level incubator cell imaging to the Americas. As the "lumanette," Etaluma will only provide InnoME's zenCell Technology. The lumanette has 24 separate 10x imagers for quick time-lapse investigations in 24 and 6-well microplates, flasks, and dishes. Simple cell coverage and counting analysis procedures are supplied as real-time data and chart presentation. Various devices that the market leaders are manufacturing are: Name of the Product Function Key Players CytoSMART Lux3 BR Used as a Live cell imaging microscope CytoSMART Zeiss Visioner 1 Real-time focus via micromirror arrays Zeiss Group Lumanette Real-time data and chart presentation. Etaluma, Inc. and InnoME, Gmbh AI Technology Turns cell morphology into a quantitative, high-throughput marker Deepcell Frequently Asked Question About This Report How big is the live cell imaging market size? The global live cell imaging market size was $1.95 billion in 2021 and is predicted to reach $4.18 billion by 2030, with a CAGR of 8.8%. The essential players in the global market? The most vital players in the global market are Danaher Corporation, Carl Zeiss AG, Nikon Corporation, Olympus Corporation, PerkinElmer, Inc., G.E. Healthcare, Bruker Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc., CytoSMART Technologies, NanoEnTek Inc., Phase Focus Limited, Tomocube Inc., Phase Holographic Imaging PHI AB, B.D. Biosciences, Sony Biotechnology Inc., Merck KGaA, KEYENCE Corporation, ibidi GmbH, Bio-Rad Laboratories, Logos Biosystems, and Nanolive SA. What are the most dominant regions of the market? Based on Regions, Asia Pacific is expected to show the highest growth rate because of the government initiatives for the research of stem cell therapy, the development of clinical research in China, and the rising demand for regenerative medicinal research. Which Technology segment held the largest share in 2021? Based on Technology, the Fluorescence resonance energy transfer segment held the largest share of the market in 2021. What is the live cell imaging market growth? The global live cell imaging market is expected to grow at a compound annual growth rate (CAGR) of 8.8% from 2021 to 2030 to reach USD $ 4.18 billion by 2030. . 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Live-cell imaging Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Live-cell imaging Market 4.2.1 Market, 2021 – 2030 (USD Million) 4.3 Regional Analysis 4.3.1 Market, By Region, 2021 - 2030 (USD Million) 4.4 By Product Analysis 4.4.1 Market, By Product, 2021 - 2030 (USD Million) 4.5 By Application Analysis 4.5.1 Market, By Application, 2021 - 2030 (USD Million) 4.6 By Technology Analysis 4.6.1 Market, By Technology, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2021) 5.11.2. Trends in Technology (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Equipment 7.3.1. Equipment Market, 2021 - 2030 (USD Million) 7.4. Software 7.4.1. Software Market, 2021 - 2030 (USD Million) 7.5. Consumables 7.5.1. Consumables Market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Cell Biology 8.3.1. Cell Biology Market, 2021 - 2030 (USD Million) 8.4. Stem Cell & Drug Discovery 8.4.1. Stem Cell & Drug Discovery Market, 2021 - 2030 (USD Million) 8.5. Developmental Biology 8.5.1. Developmental Biology Market, 2021 - 2030 (USD Million) 9. Market: By Technology Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. High content screening (HCS) 9.3.1. High content screening (HCS) Market, 2021 - 2030 (USD Million) 9.4. Fluorescence recovery after photobleaching (FRAP) 9.4.1. Fluorescence recovery after photobleaching (FRAP) Market, 2021 - 2030 (USD Million) 9.5. Time-lapse microscopy 9.5.1. Time-lapse microscopy Market, 2021 - 2030 (USD Million) 9.6. Fluorescence resonance energy transfer (FRET) 9.6.1. Fluorescence resonance energy transfer (FRET) Market, 2021 - 2030 (USD Million) 10. Market: Regional Outlook 10.1 North America 10.1.1. North America Market, By Product, 2021 - 2030 (USD Million) 10.1.2. North America Market, By Application, 2021 - 2030 (USD Million) 10.1.3. North America Market, By Technology, 2021 - 2030 (USD Million) 10.1.4. North America Market, By Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, By Product, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S. Market, By Application, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S. Market, By Technology, 2021 - 2030 (USD Million) 10.1.4.2.Canada 10.1.4.2.1. Canada Market, By Product, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada Market, By Application, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada Market, By Technology, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, By Product, 2021 - 2030 (USD Million) 10.2.2. Europe Market, By Application, 2021 - 2030 (USD Million) 10.2.3. Europe Market, By Technology, 2021 - 2030 (USD Million) 10.2.4. Europe Market, By country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, By Product, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. Market, By Application, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. Market, By Technology, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, By Product, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany Market, By Application, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany Market, By Technology, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, By Product, 2021 - 2030 (USD Million) 10.2.4.3.2. France Market, By Application, 2021 - 2030 (USD Million) 10.2.4.3.3. France Market, By Technology, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, By Product, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, By Application, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, By Technology, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, By Product, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific Market, By Application, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific Market, By Technology, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific Market, By country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, By Product, 2021 - 2030 (USD Million) 10.3.4.1.2. China Market, By Application, 2021 - 2030 (USD Million) 10.3.4.1.3. China Market, By Technology, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, By Product, 2021 - 2030 (USD Million) 10.3.4.2.2. India Market, By Application, 2021 - 2030 (USD Million) 10.3.4.2.3. India Market, By Technology, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, By Product, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan Market, By Application, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan Market, By Technology, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, By Product, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea Market, By Application, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea Market, By Technology, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, By Product, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, By Application, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, By Technology, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, By Product, 2021 - 2030 (USD Million) 10.4.2. Latin America Market, By Application, 2021 - 2030 (USD Million) 10.4.3. Latin America Market, By Technology, 2021 - 2030 (USD Million) 10.4.4. Latin America Market, By country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, By Product, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil Market, By Application, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil Market, By Technology, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, By Product, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico Market, By Application, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico Market, By Technology, 2021 - 2030 (USD Million) 10.4.4.3. Rest of the Latin America 10.4.4.3.1. Rest of the Latin America Market, By Product, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, By Application, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, By Technology, 2021 - 2030 (USD Million) 10.5. MEA 10.5.1. MEA Market, By Product, 2021 - 2030 (USD Million) 10.5.2. MEA Market, By Application, 2021 - 2030 (USD Million) 10.5.3. MEA Market, By Technology, 2021 - 2030 (USD Million) 10.5.4. MEA Market, By Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 Danaher Corporation (U.S.) 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. CARL ZEISS AG (GERMANY) 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. NIKON CORPORATION (JAPAN) 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. OLYMPUS CORPORATION (JAPAN) 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. PERKINELMER, INC. (U.S.) 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. G.E. Healthcare (U.S.) 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Bruker Corporation (U.S.) 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Thermo Fisher Scientific Inc. (U.S.) 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Sartorius AG (Germany) 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Oxford Instruments (U.K.) 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. BioTek Instruments (US) 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. Etaluma, Inc. (U.S.) 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. CytoSMART Technologies (Netherlands) 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. NanoEnTek Inc. (Korea) 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. Phase Focus Limited (U.K.) 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development 11.16. Tomocube, Inc. (South Korea) 11.16.1. Company overview 11.16.2. Financial performance 11.16.3. Product Portfolio Analysis 11.16.4. Business Strategy & Recent Development 11.17. Phase Holographic Imaging PHI AB (Sweden) 11.17.1. Company overview 11.17.2. Financial performance 11.17.3. Product Portfolio Analysis 11.17.4. Business Strategy & Recent Development 11.18. B.D. Biosciences (U.S.) 11.18.1. Company overview 11.18.2. Financial performance 11.18.3. Product Portfolio Analysis 11.18.4. Business Strategy & Recent Development 11.19. Sony Biotechnology, Inc. (U.S.) 11.19.1. Company overview 11.19.2. Financial performance 11.19.3. Product Portfolio Analysis 11.19.4. Business Strategy & Recent Development 11.20. Merck KGaA (Germany) 11.20.1. Company overview 11.20.2. Financial performance 11.20.3. Product Portfolio Analysis 11.20.4. Business Strategy & Recent Development 11.21. KEYENCE Corporation (Japan) 11.21.1. Company overview 11.21.2. Financial performance 11.21.3. Product Portfolio Analysis 11.21.4. Business Strategy & Recent Development 11.22. ibidi GmbH (Germany) 11.22.1. Company overview 11.22.2. Financial performance 11.22.3. Product Portfolio Analysis 11.22.4. Business Strategy & Recent Development 11.23. Bio-Rad Laboratories (U.S.) 11.23.1. Company overview 11.23.2. Financial performance 11.23.3. Product Portfolio Analysis 11.23.4. Business Strategy & Recent Development 11.24. Logos Biosystems (South Korea) 11.24.1. Company overview 11.24.2. Financial performance 11.24.3. Product Portfolio Analysis 11.24.4. Business Strategy & Recent Development 11.25. Nanolive SA (Switzerland) 11.25.1. Company overview 11.25.2. Financial performance 11.25.3. Product Portfolio Analysis 11.25.4. Business Strategy & Recent Development List of Tables (84 Tables) TABLE 1. MARKET, By Product, 2021-2030 (USD Million) TABLE 2. MARKET FOR Equipment, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Software, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Consumables, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET, By Application, 2021-2030 (USD Million) TABLE 6. MARKET FOR Cell Biology, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Stem Cell & Drug Discovery, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Developmental Biology, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET, BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 12. MARKET FOR High content screening (HCS), BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Fluorescence recovery after photobleaching (FRAP), BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Time-lapse microscopy, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Fluorescence resonance energy transfer (FRET), BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA MARKET, By Product, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA MARKET, BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 23. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. EUROPE MARKET, By Product, 2021-2030 (USD Million) TABLE 25. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 26. EUROPE MARKET, BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC MARKET, By Product, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC MARKET, BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 31. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 32. LAMEA MARKET, By Product, 2021-2030 (USD Million) TABLE 33. LAMEA MARKET, By Application, 2021-2030 (USD Million) TABLE 34. LAMEA MARKET, BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 35. Danaher Corporation (U.S.): COMPANY SNAPSHOT TABLE 36. Danaher Corporation (U.S.): OPERATING SEGMENTS TABLE 37. CARL ZEISS AG (GERMANY): COMPANY SNAPSHOT TABLE 38. CARL ZEISS AG (GERMANY): OPERATING SEGMENTS TABLE 39. NIKON CORPORATION (JAPAN): COMPANY SNAPSHOT TABLE 40. NIKON CORPORATION (JAPAN): OPERATING SEGMENTS TABLE 41. OLYMPUS CORPORATION (JAPAN) : COMPANY SNAPSHOT TABLE 42. OLYMPUS CORPORATION (JAPAN) : OPERATING SEGMENTS TABLE 43. PERKINELMER, INC. (U.S.): COMPANY SNAPSHOT TABLE 44. PERKINELMER, INC. (U.S.): OPERATING SEGMENTS TABLE 45. G.E. Healthcare (U.S.): COMPANY SNAPSHOT TABLE 46. G.E. Healthcare (U.S.): OPERATING SEGMENTS TABLE 47. Bruker Corporation (U.S.): COMPANY SNAPSHOT TABLE 48. Bruker Corporation (U.S.): OPERATING SEGMENTS TABLE 49. Thermo Fisher Scientific Inc. (U.S.): COMPANY SNAPSHOT TABLE 50. Thermo Fisher Scientific Inc. (U.S.): OPERATING SEGMENTS TABLE 51. Sartorius AG (Germany): COMPANY SNAPSHOT TABLE 52. Sartorius AG (Germany): OPERATING SEGMENTS TABLE 53. Oxford Instruments (U.K.): COMPANY SNAPSHOT TABLE 54. Oxford Instruments (U.K.): OPERATING SEGMENTS TABLE 55. BioTek Instruments (US): COMPANY SNAPSHOT TABLE 56. BioTek Instruments (US): OPERATING SEGMENTS TABLE 57. Etaluma, Inc. (U.S.): COMPANY SNAPSHOT TABLE 58. Etaluma, Inc. (U.S.): OPERATING SEGMENTS TABLE 59. CytoSMART Technologies (Netherlands): COMPANY SNAPSHOT TABLE 60. CytoSMART Technologies (Netherlands): OPERATING SEGMENTS TABLE 61. NanoEnTek Inc. (Korea): COMPANY SNAPSHOT TABLE 62. NanoEnTek Inc. (Korea): OPERATING SEGMENTS TABLE 63. Phase Focus Limited (U.K.): COMPANY SNAPSHOT TABLE 64. Phase Focus Limited (U.K.): OPERATING SEGMENTS TABLE 65. Tomocube, Inc. (South Korea): COMPANY SNAPSHOT TABLE 66. Tomocube, Inc. (South Korea): OPERATING SEGMENTS TABLE 67. Phase Holographic Imaging PHI AB : COMPANY SNAPSHOT TABLE 68. Phase Holographic Imaging PHI AB : OPERATING SEGMENTS TABLE 69. B.D. Biosciences (U.S.): COMPANY SNAPSHOT TABLE 70. B.D. Biosciences (U.S.): OPERATING SEGMENTS TABLE 71. Sony Biotechnology, Inc. (U.S.): COMPANY SNAPSHOT TABLE 72. Sony Biotechnology, Inc. (U.S.): OPERATING SEGMENTS TABLE 73. Merck KGaA (Germany): COMPANY SNAPSHOT TABLE 74. Merck KGaA (Germany): OPERATING SEGMENTS TABLE 75. KEYENCE Corporation (Japan): COMPANY SNAPSHOT TABLE 76. KEYENCE Corporation (Japan): OPERATING SEGMENTS TABLE 77. ibidi GmbH (Germany): COMPANY SNAPSHOT TABLE 78. ibidi GmbH (Germany): OPERATING SEGMENTS TABLE 79. Bio-Rad Laboratories (U.S.): COMPANY SNAPSHOT TABLE 80. Bio-Rad Laboratories (U.S.): OPERATING SEGMENTS TABLE 81. Logos Biosystems (South Korea): COMPANY SNAPSHOT TABLE 82. Logos Biosystems (South Korea): OPERATING SEGMENTS TABLE 83. Nanolive SA (Switzerland): COMPANY SNAPSHOT TABLE 84. Nanolive SA (Switzerland): OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 25 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Live-cell imaging, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Live-cell imaging, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Technology, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Equipment to Witness Higher CAGR in the Market for Product Segment during Forecast Period. Figure 16 Fluorescence recovery after photobleaching (FRAP) to Witness Higher CAGR in the Market for Technology Segment during Forecast Period. Figure 17 Cell Biology to Witness Higher CAGR in the Market for Application Segment during Forecast Period. Figure 18 Asia Pacific region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview